Experimental Study on Improving Radiosensitivity for Lewis Lung Cancer with Gemcitabine

Shu-juan LI,Jin-jun JIANG,Chun-xue BAI
DOI: https://doi.org/10.3760/cma.j.issn.1673-436X.2005.02.002
2005-01-01
Abstract:Objective Gemcitabine (dFdC) is an analogue of nucleoside.By incorporating into DNA strand,it can halt elongating DNA and kill tumor cells.The aim of this study was to determine the radiosensitivity on Lewis lung cancer with gemcitabine.Methods Mice bearing Lewis tumor were randomly divided into-control,radiation,gemcitabine and combination of gemcitabine with radiation groups.The parameters of tumor growth,inhibition of growth,the number of surviving mice and metastasis were observed after treatment.Results Single dose of 25mg/kg or 50mg/kg of gemcitabine had significant inhibiting effect on the growth of Lewis tumor.Tumor growth inhibition in combination group ( 86.6%) was higher than that of radiation group and gemcitabine group ( 64.7% and 47.3%,respectively,P 0.05).Time of tumor growth delay (volume from 0.3 to 1.0cm 3) was beyond 12 days in combination group,3 days and 6 days in radiation group and gemcitabine group,respectively (P 0.05).4 mice survived beyond 60 days in combination group,2 mice in radiation group,and none in the other two groups.The number of lung metastatic tumor in combination group was 0.5 per lung lobe,which was fewer than that in control group ( 3.2 per lung lobe,P 0.01),radiation group ( 1.5 per lung lobe,P 0.05),and gemcitabine group ( 1.8 per lung lobe,P 0.05).Conclusions Gemcitabine could increase radiosensitivity of Lewis tumor and result in significant inhibition of growth of tumor and metastasis.The results showed that it was a better method to treat tumor by radiotherapy combined with gemcitabine.
What problem does this paper attempt to address?